Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity

Neurobiology of Disease

Volumn 46, Issue 1, 2012, Pages 69-77

  Lopez, S ^a,b   Jouve, L ^c   Turle Lorenzo, N ^a,b   Kerkerian LeGoff, L ^c   Salin, P ^c   Amalric, M ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

6 Hydroxydopamine (6 OHDA); Basal ganglia; Glutamate; In situ hybridization; Rat; Reaction time task

Indexed keywords

1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; ANTIPARKINSON AGENT; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE SUBUNIT 1; MESSENGER RNA; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CATALEPSY; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION REGULATION; GLOBUS PALLIDUS; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RESPONSE TIME; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; TASK PERFORMANCE;

ANIMALS; CYCLOPENTANES; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; MALE; NEURAL PATHWAYS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; STEREOISOMERISM; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; TRICARBOXYLIC ACIDS;

EID: 84858155508     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.045     Document Type: Article

References (38)

1. Acher F.C., et al. Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J. Med. Chem. 1997, 40:3119-3129.
2. Albin R.L., et al. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
3. Amalric M., et al. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur. J. Neurosci. 1995, 7:972-980.
4. Awad-Granko H., Conn P.J. Activation of groups I or III metabotropic glutamate receptors inhibits excitatory transmission in the rat subthalamic nucleus. Neuropharmacology 2001, 41:32-41.
5. Beurrier C., et al. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009, 23:3619-3628.
6. Bradley S.R., et al. Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. J. Comp. Neurol. 1999, 407:33-46.
7. Breysse N., et al. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 2003, 23:8302-8309.
8. Conn P.J., et al. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 2005, 6:787-798.
9. Corti C., et al. Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience 2002, 110:403-420.
10. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990, 13:281-285.
11. Deniau J.M., et al. The pars reticulata of the substantia nigra: a window to basal ganglia output. Prog. Brain Res. 2007, 160:151-172.
12. Duty S. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br. J. Pharmacol. 2010, 161:271-287.
13. Galvan A., et al. Glutamate and GABA receptors and transporters in the basal ganglia: what does their subsynaptic localization reveal about their function?. Neuroscience 2006, 143:351-375.
14. Goudet C., et al. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 2007, 137:112-124.
15. Hamani C., et al. The subthalamic nucleus in the context of movement disorders. Brain 2004, 127:4-20.
16. Joel D., Weiner I. The connections of the primate subthalamic nucleus: indirect pathways and the open-interconnected scheme of basal ganglia-thalamocortical circuitry. Brain Res. Brain Res. Rev. 1997, 23:62-78.
17. Joel D., Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000, 96:451-474.
18. Konieczny J., et al. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience 2007, 145:611-620.
19. Kosinski C.M., et al. Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J. Comp. Neurol. 1999, 415:266-284.
20. Lopez S., et al. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J. Neurosci. 2007, 27:6701-6711.
21. Lopez S., et al. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology 2008, 55:483-490.
22. Macinnes N., Duty S. Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo. Eur. J. Pharmacol. 2008, 580:95-99.
23. MacInnes N., et al. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br. J. Pharmacol. 2004, 141:15-22.
24. Marino M.J., et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13668-13673.
25. Mathiesen J.M., Ramirez M.T. The metabotropic glutamate receptor 4 is internalized and desensitized upon protein kinase C activation. Br. J. Pharmacol. 2006, 148:279-290.
26. Matsui T., Kita H. Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus. Neuroscience 2003, 122:727-737.
27. Messenger M.J., et al. Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract. Neuropharmacology 2002, 43:261-271.
28. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322.
29. Ossowska K., et al. An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 2007, 32:179-188.
30. Oueslati A., et al. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur. J. Neurosci. 2005, 22:2765-2774.
31. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Academic Press, Sydney.
32. Pelkey K.A., et al. mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082. Neuropharmacology 2007, 52:108-117.
33. Testa C.M., et al. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 1994, 14:3005-3018.
34. Turle-Lorenzo N., et al. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J. Pharmacol. Exp. Ther. 2006, 319:914-923.
35. Valenti O., et al. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J. Neurosci. 2003, 23:7218-7226.
36. Wichmann T., DeLong M.R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 1996, 6:751-758.
37. Wittmann M., et al. Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J. Pharmacol. Exp. Ther. 2002, 302:433-441.
38. Zhang C., Albin R.L. Increased response to intrastriatal l(+)-2-amino-4-phosphonobutyrate (l-AP4) in unilateral 6-hydroxydopamine-lesioned rats. Exp. Neurol. 2000, 165:278-284.